Skin ulcerative defects therapy in chronic venous insufficiency
- Authors: Sakaniya L.R.1,2, Chekh A.S.1, Korsunskaya I.M.2
-
Affiliations:
- Moscow Research and Practical Center of Dermatovenereology and Cosmetology, Moscow Healthcare Department
- Center for Theoretical Problems of Physicochemical Pharmacology, Russian Academy of Sciences
- Issue: Vol 34, No 8 (2023)
- Pages: 79-81
- Section: From Practice
- URL: https://journals.eco-vector.com/0236-3054/article/view/569091
- DOI: https://doi.org/10.29296/25877305-2023-08-15
- ID: 569091
Cite item
Abstract
Chronic venous insufficiency (CVI) is characterized by various symptoms and manifestations, including skin manifestations, among which venous eczema is the most common – about 44% of patients. The itching associated with eczema leads to scratching, which in turn increases the chances of secondary infections. In addition, venous ulceration of the lower extremities often develops in CVI, which can also be complicated by secondary infection, making the choice of therapy difficult. The treatment of venous eczema uses combined glucocorticosteroids, which relieve pruritus and infectious complications, as well as care products with a pronounced moisturizing effect. In the presence of ulcerative defects it is necessary to use means for cleansing of the wound surface and acceleration of epithelization processes.
Full Text
About the authors
L. R. Sakaniya
Moscow Research and Practical Center of Dermatovenereology and Cosmetology, Moscow Healthcare Department; Center for Theoretical Problems of Physicochemical Pharmacology, Russian Academy of Sciences
Author for correspondence.
Email: marykor@bk.ru
ORCID iD: 0000-0003-2027-5987
Candidate of Medical Sciences
Russian Federation, Moscow; MoscowA. S. Chekh
Moscow Research and Practical Center of Dermatovenereology and Cosmetology, Moscow Healthcare Department
Email: marykor@bk.ru
ORCID iD: 0009-0009-8985-3387
Russian Federation, Moscow
I. M. Korsunskaya
Center for Theoretical Problems of Physicochemical Pharmacology, Russian Academy of Sciences
Email: marykor@bk.ru
ORCID iD: 0000-0002-6583-0318
MD, Professor
Russian Federation, MoscowReferences
- Matić M., Matić A., Gajinov Z. et al. Major risk factors for chronic venous disease development in women: is childbirth among them? Women Health. 2019; 59 (10): 1118–27. doi: 10.1080/03630242.2019.1590492
- Lacroix P., Aboyans V., Preux P.M. et al. Epidemiology of venous insufficiency in an occupational population. Int Angiol. 2003; 22 (2): 172–6.
- Branisteanu D.E., Feodor T., Baila S. et al. Impact of chronic venous disease on quality of life: Results of vein alarm study. Exp Ther Med. 2019; 17 (2): 1091–6. doi: 10.3892/etm.2018.7054
- Serra R., Buffone G., de Franciscis A. et al. A genetic study of chronic venous insufficiency. Ann Vasc Surg. 2012; 26 (5): 636–42. doi: 10.1016/j.avsg.2011.11.036
- Serra R., Grande R., Butrico L. et al. Epidemiology, diagnosis and treatment of chronic venous disease: A systematic review. Chirurgia. 2016; 29: 34–45.
- Serra R., Grande R., Buffone G. et al. Chronic venous disease is more aggressive in patients with varicocele. Acta Phlebol. 2013; 14 (2): 57–60.
- Beebe-Dimmer J.L., Pfeifer J.R., Engle J.S. et al. The epidemiology of chronic venous insufficiency and varicose veins. Ann Epidemiol. 2005; 15 (3): 175–84. doi: 10.1016/j.annepidem.2004.05.015
- Serra R., Butrico L., Ruggiero M. et al. Epidemiology, diagnosis and treatment of chronic leg ulcers: a systematic review. Acta Phlebol. 2015; 16: 9–18.
- de Franciscis S., Nobile C.G.A., Larosa E. et al. Air contamination in the sclerosing foam for the treatment of varicose veins. Phlebology. 2016; 31 (2): 96–100. doi: 10.1177/0268355514565194
- Eklöf B., Rutherford R.B., Bergan J.J. et al. American Venous Forum International Ad Hoc Committee for Revision of the CEAP Classification. Revision of the CEAP classification for chronic venous disorders: consensus statement. J Vasc Surg. 2004; 40 (6): 1248–52. doi: 10.1016/j.jvs.2004.09.027
- Rabe E., Pannier F. Clinical, aetiological, anatomical and pathological classification (CEAP): gold standard and limits. Phlebology. 2012; 27 (Suppl 1): 114–8. doi: 10.1258/phleb.2012.012s19
- Serra R., Buffone G., Costanzo G. et al. Altered Metalloproteinase-9 expression as the least common denominator between varicocele, inguinal hernia and chronic venous disorders. Ann Vasc Surg. 2014; 28 (3): 705–9. doi: 10.1016/j.avsg.2013.07.026
- Amato B., Coretti G., Compagna R. et al. Role of matrix metalloproteinases in non-healing venous ulcers. Int Wound J. 2015; 12 (6): 641–5. doi: 10.1111/iwj.12181
- Serra R., Buffone G., Falcone D. et al. Chronic venous leg ulcers are associated with high levels of metalloproteinases-9 and neutrophil gelatinase-associated lipocalin. Wound Repair Regen. 2013; 21 (3): 395–401. doi: 10.1111/wrr.12035
- Tracz E., Zamojska E., Modrzejewski A. et al. Quality of life in patients with venous stasis ulcers and others with advanced venous insufficiency. Holist Nurs Pract. 2015; 29 (2): 96–102. doi: 10.1097/HNP.0000000000000072
- Yao P.Y., Mukhdomi T. Varicose Vein Treatment: Endovenous Laser Therapy. 2023 May 18. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2023.
- Rzepecki A.K., Blasiak R. Stasis dermatitis: differentiation from other common causes of lower leg inflammation and management strategies. Curr Geriat Rep. 2018; 7 (4): 222–7. doi: 10.1007/s13670-018-0257-x
- Sundaresan S., Migden M.R., Silapunt S. Stasis dermatitis: pathophysiology, evaluation, and management. Am J Clin Dermatol. 2017; 18 (3): 383–90. doi: 10.1007/s40257-016-0250-0
- Theodosat A. Skin diseases of the lower extremities in the elderly. Dermatol Clin. 2004; 22 (1): 13–21. doi: 10.1016/S0733-8635(03)00113-X
- Payne D. Venous eczema: more than just a rash. Br J Community Nurs. 2023; 28 (6): 298–300. doi: 10.12968/bjcn.2023.28.6.298
- Kirkup M.E. Xerosis and stasis dermatitis. Preventive Dermatology. London: Springer, 2011; p. 71–9.
- Heilesen B. Studies on the therapeutic effect of trypsin. J Invest Dermatol. 1954; 23 (1): 7–15. doi: 10.1038/jid.1954.77
- Воронина Т.А. Мексидол, основные эффекты, механизм действия, применение. М., 2004; с. 21 [oronina T.A. Meksidol, osnovnye effekty, mekhanizm deistviya, primenenie. M., 2004; р. 21 (in Russ.)].
- Çakici N., Fakkel T.M., van Neck J.W. et al. Systematic review of treatments for diabetic peripheral neuropathy. Diabet Med. 2016; 33 (11): 1466–76. doi: 10.1111/dme.13083